Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Discovery Laboratories reports net loss of $6.3 million for second-quarter 2010

Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant and related aerosolization technologies as first in class therapies for severe respiratory diseases, today provides an update on key pipeline and business initiatives and reports financial results for the second quarter ended June 30, 2010.

4 Aug 2010

Nuokang's product pipeline candidates advance through SFDA review process

China Nuokang Bio-Pharmaceutical Inc., a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that two of its product pipeline candidates recently advanced through the next respective stages of the State Food and Drug Administration review process.

4 Aug 2010

Insmed second-quarter net loss decreases to $0.4 million

Insmed Inc., a biopharmaceutical company, today reported results for the second quarter and six-months ended June 30, 2010.

4 Aug 2010

TSO3 second-quarter net loss decreases to $1.9 million

TSO3 Inc. an innovator in sterilization technology for medical devices in healthcare settings using ozone, posted revenues of $494,353 for the sales of new generation sterilizers (STERIZONE(R) 125L+ / 3M(TM) Optreoz(TM) 125-Z), accessories and service contracts. This compares to $510,626 for the same period in 2009, representing the sale of two of the first generation ozone sterilizers (125L), accessories and service contracts, as well as a large installation contract.

4 Aug 2010

Pew Prescription Project announces support for new safety legislation

The Pew Prescription Project, joined by major consumer, physician and chemical manufacturer groups, today announced support for a new bill that would give the U.S. Food and Drug Administration much-needed authorities to better protect pharmaceutical supply chains. The organizations made the announcement in a joint letter to Congress and during an audio news conference with Senator Michael Bennet (D-CO), who will introduce this drug safety legislation.

4 Aug 2010

Savient second-quarter net loss decreases to $5.0 million

Savient Pharmaceuticals, Inc. reported financial results for the three and six months ended June 30, 2010. The net loss for the second quarter of 2010 was $5.0 million, or $0.07 per basic and diluted share, on total revenues of $1.0 million, compared with a net loss of $54.8 million, or $0.92 per basic and diluted share on total revenues of $0.7 million for the second quarter of 2009.

4 Aug 2010

Matrixx Initiatives first-quarter net loss reduces to $2.4 million

Matrixx Initiatives, Inc., an over-the-counter healthcare company that develops and markets Zicam® products, today announced financial results for its fiscal first quarter ended June 30, 2010.

4 Aug 2010

Bayer implements ValGenesis validation process management software at Berkeley and Emeryville sites

ValGenesis, Inc., a world-leading provider of Validation Lifecycle Management (VLM) software solutions, today announced that Bayer HealthCare AG has implemented ValGenesis software as their platform for validation process management at their Berkeley and Emeryville sites.

4 Aug 2010

Dendreon second-quarter revenue increases to $2.8 million

Dendreon Corporation today reported results for the quarter ended June 30, 2010. Revenue for the quarter ended June 30, 2010 was $2.8 million compared to $25,000 for the quarter ended June 30, 2009. Revenue for the six months ended June 30, 2010 was $2.8 million compared to $55,000 for the six months ended June 30, 2009.

4 Aug 2010

Arena reports lower net loss of $28.80M for second-quarter 2010

Arena Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010, and recent developments, including the successful Pre-Approval Inspection, or PAI, of the company's Swiss drug product manufacturing facility by the US Food and Drug Administration, or FDA.

4 Aug 2010

Enzon second-quarter loss from continuing operations reduces to $5.4 million

Enzon Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2010. For the second quarter of 2010, Enzon reported a loss from continuing operations of $5.4 million or $0.09 per diluted share, as compared to a loss of $19.7 million or $0.43 per diluted share for the second quarter of 2009.

4 Aug 2010

West Pharmaceutical Services second-quarter gross profit increases 5.8% to $83.2 million

West Pharmaceutical Services, Inc. today announced its financial results for the second quarter of 2010.

3 Aug 2010

Caliper Life Sciences second-quarter GAAP revenue decreases 10% to $29.0 million

Caliper Life Sciences, Inc., today reported results for its second quarter ended June 30, 2010. Second quarter GAAP revenue decreased 10% to $29.0 million from $32.1 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 4% on a reported basis and 6% on an organic basis (which assumes constant currency).

3 Aug 2010

IntegenX selects Zeta's 3D to analyze dimensional properties of micro-channel biochips

Zeta Instruments, Inc. a leading provider of cost-effective, precision measurement solutions for micron-scale surface analysis, announced that its Zeta-20™ optical metrology system has been selected for the analysis and development of advanced microfluidics/biotechnology laboratory products. IntegenX, an innovative supplier of automation systems for DNA and RNA-based micro-sample preparation used in forensics and gene sequencing, has chosen Zeta's 3D surface measurement solution to analyze the dimensional properties of its micro-channel biochips.

3 Aug 2010

MRCC deploys CTT's Calmare Pain Therapy Treatment medical device

Competitive Technologies, Inc. announced that McKinney Regional Cancer Care Center, a private physician oncology practice based in McKinney, TX, is the first cancer center in Texas treating with CTT's Calmare Pain Therapy Treatment medical device. Patients suffering from pain related to cancer are being treated under the direction of medical oncologist Dennis Birenbaum, M.D.

3 Aug 2010

BioMarin reports $0.5 million GAAP net loss for second-quarter 2010

BioMarin Pharmaceutical Inc. today announced financial results for the second quarter of 2010. GAAP net loss was $0.5 million ($0.01 per diluted share) for the second quarter of 2010, compared to GAAP net income of $1.3 million ($0.01 per diluted share) for the second quarter of 2009. Non-GAAP net income was $8.6 million ($0.08 per diluted share) for the second quarter of 2010, compared to non-GAAP net income of $9.0 million ($0.09 per diluted share) for the second quarter of 2009.

3 Aug 2010

Orthovita second-quarter operating income improves to $0.4 million

Orthovita, Inc., an orthobiologics and biosurgery company, reported financial results for the quarter ended June 30, 2010. Product sales for the second quarter of 2010 were $23.9 million compared to $24.5 million for the second quarter of 2009. Product sales for the second quarter of 2009 included $0.6 million from the sale of Vitomatrix™, a bone graft material used in dental products. There were no Vitomatrix sales in the second quarter of 2010 and no further sales of Vitomatrix are currently expected.

3 Aug 2010

RoundTable announces establishment of new platform business in ophthalmology market

RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has established a platform business in the ophthalmology market. The new platform company, Beaver-Visitec International, Inc., consists of ophthalmology products and assets recently acquired from BD and Medtronic, Inc.

2 Aug 2010

MannKind second-quarter total operating expenses decrease to $16.0 million

MannKind Corporation today reported financial results for the second quarter ended June 30, 2010.

2 Aug 2010

INEOS agrees to sell Global Films business to Bilcare AG

INEOS Group has today entered into a binding agreement for the sale of its Global Films business to Bilcare AG, one of the world's leading providers of research led packaging to the global pharmaceuticals industry, for approximately EUR100 million. The agreement brings together complimentary capabilities and synergy's of two leading global businesses.

2 Aug 2010